12:00 AM
 | 
Sep 20, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Remicade infliximab: Phase III data; sBLA under review to reduce the signs and symptoms of RA; marketed to treat Crohn's disease

Based on one-year x-ray data from CNTO's 428-patient Phase III ATTRACT trial, which showed that the combination of Remicade and methotrexate arrested joint damage, a Safety Monitoring Committee recommended that the placebo...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >